Balance Sheet
Cash Flow Statement
Amortization of Deferred ChargesAmortizatization of IntangiblesCapital ExpendituresCash from Financing ActivitiesCash from Investing ActivitiesCash from OperationsChange in Account PayablesChange in Accured ExpensesChange in CashChange in InventoryChange in ReceivablesDeferred TaxesDepreciation & Amortization (CF)Exchange Rate EffectFree Cash FlowGains from Investment SecuritiesNet Cash FlowNet IncomeNon-cash ItemsOther financing activitiesShare-based CompensationShares Issued
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Orthofix Medical (OFIX) Gains from Sales and Divestitures (2016 - 2021)

Orthofix Medical (OFIX) has disclosed Gains from Sales and Divestitures for 11 consecutive years, with $86542.0 as the latest value for Q4 2021.

  • For the quarter ending Q4 2021, Gains from Sales and Divestitures rose 16.89% year-over-year to $86542.0, compared with a TTM value of $86542.0 through Dec 2021, up 16.89%, and an annual FY2021 reading of $86542.0, up 16.89% over the prior year.
  • Gains from Sales and Divestitures was $86542.0 for Q4 2021 at Orthofix Medical, up from $74036.0 in the prior quarter.
  • Across five years, Gains from Sales and Divestitures topped out at $157807.0 in Q4 2017 and bottomed at $27982.0 in Q4 2018.
  • Average Gains from Sales and Divestitures over 5 years is $78688.8, with a median of $74036.0 recorded in 2020.
  • The sharpest move saw Gains from Sales and Divestitures crashed 82.27% in 2018, then soared 68.24% in 2019.
  • Year by year, Gains from Sales and Divestitures stood at $157807.0 in 2017, then plummeted by 82.27% to $27982.0 in 2018, then skyrocketed by 68.24% to $47077.0 in 2019, then skyrocketed by 57.27% to $74036.0 in 2020, then grew by 16.89% to $86542.0 in 2021.
  • Business Quant data shows Gains from Sales and Divestitures for OFIX at $86542.0 in Q4 2021, $74036.0 in Q4 2020, and $47077.0 in Q4 2019.